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Abstract 
Trastuzumab is a humanized monoclonal antibody approved for treatment of HER2 (human epidermal growth factor 2) 
positive breast cancer. Conjugation of trastuzumab offers a promising strategy of selective anticancer therapy. Trastuzumab-
emtansin is a new generation of cytotoxic drug conjugated antibody with higher tumour selectivity and less toxicity of 
emtansin. Conjugates of trastuzumab with bifunctional chelators (BFCs) for further radiolabelling are a step ahead in the field 
of radiopharmacy for therapy and imaging of aggressive HER2 positive cancers. The purpose of this study is characterization 
of integrity and secondary structure of antibody in already formulated lyophilized conjugates with p-SCN-Bn-DTPA- and p-
SCN-Bn-1B4M-DTPA- by applying SDS-PAGE electrophoresis and Raman spectroscopy. The results are positive and give 
an opportunity for further radiolabelling of freeze dried conjugates. 
 
Rezumat 
Trastuzumab este un anticorp monoclonal umanizat, aprobat pentru tratamentul cancerului de sân HER 2 (factorul de creștere 
epidermal uman 2) pozitiv. Conjugarea trastuzumabului oferă o strategie promițătoare de terapie selectivă împotriva acestei 
afecțiuni. Trastuzumab-emtansin este o nouă generație de anticorpi conjugați cu medicamente citotoxice, cu o selectivitate 
crescută asupra tumorii și o mai mică toxicitate datorită emtansinei. Conjugatele trastuzumabului cu chelatori bifuncționali 
(BFC) pentru radiomarcare ulterioară sunt un pas înainte în domeniul radiofarmaceutic pentru terapia și imagistica  
cancerelor HER 2 pozitive agresive. Scopul acestui studiu a fost caracterizarea integrității și a structurii secundare a 
anticorpului în conjugatele liofilizate, formulate cu p-SCN-Bn-DTPA- și p-SCN-Bn-1B4M-DTPA-, prin aplicarea 
electroforezei SDS-PAGE și a spectroscopiei RAMAN. Rezultatele sunt promițătoare și oferă o oportunitate pentru marcarea 
ulterioară a derivaților conjugați. 
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Introduction 
HER2 receptor (Human epidermal growth factor 2) 
is a part of tyrosine kinase receptor family. Over-
expression and amplification of HER2 has been 
associated with 20 - 30% of patients with primary 
breast cancer. This condition is correlated with 
aggressive and metastatic carcinoma with poor clinical 
prognosis [4, 17]. Due to the easy availability of the 
extracellular domain of HER2 and high affinity binding 
of trastuzumab to the receptor, Herceptin® was 
approved for treatment of aggressive HER2 positive 
cancers [11]. Trastuzumab, humanized monoclonal 
antibody, has shown significant improvement of clinical 
condition of patient, particularly in combined 
administration with other cytotoxic drugs [25]. The 
binding of naked monoclonal antibodies with cytotoxic 
drugs achieves higher tumour selectivity of drugs 
that are too toxic to be separately used. Conjugation 
of drugs with antibodies reduces the risk of drug 
resistance [7]. After many years of examinations in 
the field of HER2 positive cancers, a novel, more 
stable, conjugate of trastuzumab is formulated –  
trastuzumab-emtansine (T-DM1), which is approved 
for treatment of advanced metastatic breast cancer. The 
T-DM1 shows better activity and selectivity compared 
with naked antibody [22]. Besides the cytotoxic drug-
trastuzumab conjugation, radiolabelling of the anti-
body via BFCs is crucial for development of therapeutic 
and potent agents for molecular imaging and 
identification of metastatic lesions [2]. Significant 
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radiopharmaceuticals, based on peptide and anti-
body, designed for diagnostic and therapeutically 
purpose involve different radioisotopes (99mTc/188Re, 
67Ga, 177Lu, 90Y, 131I, 18F). Several studies have shown 
that already existing radiolabelled formulations, using 
beta and alfa emitters (90Y, 86Y, 177Lu, 227Th, 225Ac) are 
potent against HER2 positive breast cancer [21, 28]. 
The most sensitive marker for detecting hypermetabolic 
sites and identification of metastatic lesions are: γ 
camera (planar scintigraphy), computed tomography 
and positron emission tomography (PET) [10]. Until 
now, the most investigated BFCs for successful 
labelling of proteins and antibodies are: DOTA 
(1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic 
acid), DTPA (diethylene triamine pentaacetic acid), 
TCMC (1,4,7,10-tetra-(2-carbamoyl methyl)-cyclo-
dodecane), HYNIC (succinimidyl-6-hydrazino-nicotin-
amide) and DTPA derivate 1B4M-DTPA (2-(4-iso-
thiocyanatobenzyl)-6-methyl-diethylene-triamine-
pentaacetic acid) [3].  
The purpose of this study was the characterization 
of possible changes in secondary structure of anti-
body after freeze dried kit formulation with p-SCN-Bn-
1B4M-DTPA (2-(4-isothiocyanatobenzyl)-6-methyl-
diethylene-triaminepentaacetic acid) and p-SCN-Bn-
DTPA (2-(4-izothiocyanatobenzyl)-diethylenetri-
aminepentaacetic acid) (Figure 1), by using SDS-
PAGE electrophoresis under reducing conditions and 
Raman spectroscopy. 
 
 
Figure 1. 
Chemical structure of chelators for trastuzumab 
conjugation 
 
Materials and Methods 
Trastuzumab-BFCs conjugation. The chelators prepared 
as 10 mg/mL solutions, were mixed with purified 
antibody from Herceptin® (Hoffmann-La Roche, Basel, 
Switzerland), in 10 and 50-fold molar excess by 
gentle shaking for 18 hours at 4ºC. The purification of 
antibodies and conjugates were made with Amicon® 
Ultra-4, 30 kDa (Sigma Aldrich, Missouri, USA) in six 
cycles, using HuMax 4k (Human, Wiesbaden, Germany) 
centrifuge. The concentration of trastuzumab-conjugates 
was adjusted to 1 mg/mL using the 6715 UV/Vis 
Spectrophotometer Jenway® (Staffordshire, UK). 
Process of freeze drying. Modified protocol from 
Gjorgieva Ackova et al. [8] was applied for freeze 
drying process, using Labconco Free Zone Stoppering 
Tray Dryer (Kansas City, Missouri, USA). The volume 
of 1 mL of the liquid immunoconjugates was 
transferred to type I glass vials and equally placed 
on the shelves after reaching the temperature of 
4°C. The freezing step was performed at -40ºC at a 
rate of 1ºC/min and the hold time for 5 hours. The 
primary drying was performed at pressure of 0.133 
mBar and temperature of -10ºC at a rate of 0.15ºC/ 
min and held for 28 hours. For secondary drying the 
temperature was reached to 25ºC at a rate of 0.2ºC/ 
min for 14 hours. After completing the whole process, 
the vials were closed and kept at 4°C in order to 
perform the following examinations. 
SDS-PAGE for antibody integrity analysis. SDS-PAGE 
electrophoresis was performed with Enduro® Modular 
Vertical Gel Electrophoresis System (Labnet, Edison, 
NJ, USA), in reduced conditions (2-mercaptoethanol). 
According to the protocol of the manufacturer, 12% 
separating acrylamide/bisacrylamide gel and 4% 
stacking gel were prepared. To 30 µg of the sample 
with concentration of 1 mg/mL was added 10 µL of 
loading buffer. The mixtures were heated 5 min at dry 
bath at 98.5ºC and centrifuged for 5 min at 5000 rpm. 
25 µL of every sample and 10 µL of SigmaMarkerTM, 
Wide Range, Molecular Weight (Saint Louis, MO, 
USA) were applied in wells of stacking gel. According 
to our experience, constant voltage at 150 V and 
approximately current at 23 mA have been used. 
Coomassie staining was performed after finishing the 
entire process. All used reagents were from Sigma-
Aldrich (Missouri, USA). The prepared gel was 
scanned with Glite 900 BW Gel Scanner (PacificImage, 
Torrance, CA). 
Raman spectroscopy to monitor protein secondary 
structure. Freeze dried samples were directly applied 
under the laser beam of the instrument. The room 
temperature Raman spectra (2000 - 100 cm-1) were 
recorded on micro-Raman multichannel spectrometer 
Horiba Jobin Yvon LabRam 300 Infinity. The Raman 
effect was obtained using 632.8 nm from a He:Ne 
laser, without the use of the attenuation filter. An 
Olympus MPlanN confocal microscope with ×50 
objective was selected and the spectral resolution 
was set to 4 cm-1. A confocal hole of about 2 µm was 
used and the position on the sample surface was 
manipulated by a motorized x-y stage. The Raman 
shift was calibrated by using the Raman peak of silica 
located at 520.7 cm-1. The acquisition time and the 
accumulation number were set to 20 s and 20 scans, 
respectively. 
 
Results and Discussion 
The most important goal of process of antibody-
immunoconjugates formulation as therapeutic or 
diagnostic agents is to reduce the protein degradation. 
Antibodies are not stable in a liquid form and the 
process of freeze drying is one of the commonly 
approaches for the protein stabilization. The degradation 
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of the antibody during storage can be chemically 
(deamidation, isomerization, oxidation, fragmentation) 
and physically (denaturation, aggregation, surface 
adsorption) and may reduce the activity of the anti-
body. Lyophilized antibodies are more stable than 
liquid formulations. The process of lyophilisation can 
also damage the antibody and a proper formulation 
should maximize the activity of the antibody and 
prevent any changes in secondary structure [14, 19, 
29]. One protocol to protect the antibody from stress 
temperature during the lyophilisation process is the 
addition of cryoprotectantes. In our case, we have 
been used 1% mannitol, 50 µL in each vial. Besides this 
role, the mannitol is a bulking agent and is important 
to obtain fluffy cakes for easy reconstitution. 
In a process of preparation of four freeze dried kits 
of trastuzumab with p-SCN-Bn-1B4M-DTPA and 
p-SCN-Bn-DTPA in ratio 1:10 and 1:50 it is 
important to determine the physicochemical stability. 
Many instrumental techniques can be used to establish 
the possible changes and degradation in the protein 
after conjugation and freeze drying. As a part of 
this research we have been used SDS-PAGE under 
reducing condition and Raman spectroscopy in order 
to test the integrity, purity, possible aggregation and 
modifications in secondary protein structure of the 
trastuzumab. The four conjugated samples were 
reconstituted in concentration of 1 mg/mL before 
mixing with loading buffer. Purified trastuzumab in 
concentration of 1 mg/mL has been used as a control 
sample. The scanned gel with all five samples and 
the marker is shown in Figure 2.  
 
 
Figure 2. 
Reducing SDS-PAGE of Trastuzumab 1 mg/mL (1); p-SCN-Bn-DTPA-Trastuzumab (1:10) (2); 
p-SCN-Bn-DTPA-Trastuzumab (1:50) (3); p-SCN-Bn-1B4M-DTPA-Trastuzumab (1:10) (4); 
p-SCN-Bn-1B4M-DTPA-Trastuzumab (1:50) (5) 
 
The integrity testing of trastuzumab-immunoconjugates 
has been made by applying of SDS-PAGE in reducing 
or non-reducing conditions. Under reducing conditions, 
IgG1 antibodies were migrated as two bands a ∼ 50 
kDa and ∼ 25 kDa (Mr of heavy and light chain), 
while under non-reducing conditions were observed 
only one band at ~ 150 kDa (Mr of whole antibody) 
[18]. Our obtained results have shown the fragments 
with the same molecular masses like already published 
results for other IgG1 monoclonal antibodies. In a 
presence of 2-mercaptoethanol, disulphide bones 
were reduced and trastuzumab-immunoconjugates 
were separated in two bands of fragments with 
molecular weight of 25 kDa for light chain and 50 
kDa for heavy chain (proven by the used marker). 
The same intensity and the same Mr of the fragments 
of freeze dried BFCs-trastuzumab conjugates with 
the fragments of commercial unmodified trastuzumab 
was indicated that no changes occurred in the structure 
of the antibody. The results have shown that the 
formulation of freeze dried kits is successful, without 
any degradation, denaturation, fragmentation and 
aggregation of trastuzumab. 
Acceptable electrophoretic results give the opportunity 
for further investigations. Possible destruction of anti-
body native structure can be identifying with various 
instrumental techniques. Raman and infrared (IR) 
spectrometers are suitable for studies of protein 
pharmaceuticals. IR spectroscopy is an oldest 
experimental method for characterization of structural 
features of proteins that requires minimal sample 
preparation and high speed of getting the spectra. 
On the other hand, Raman spectroscopy is a suitable 
method for determination of any folding, assembly and 
protein aggregation. It is a newer technique which 
can be used for measurement of aqueous solutions 
and protein therapeutics at very low concentration 
of 1 mg/mL [13, 27, 30, 31]. In this study, Raman 
spectroscopy was used for examination of secondary 
structure of trastuzumab-immunoconjugates and pure 
antibody as a comparison (Figure 3). This spectroscopy 
is a scattering technique and the produced signal is 
unique for every atom or molecule [13]. Trastuzumab, 
like other IgG1 antibodies, has molecular weight of 
~ 150 kDa and structure mostly arranged of beta 
sheets, several beta turns, small part of alpha helix 
 
 
 
 
 
 
 
 
 
50 kDa 
25 kDa 
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and disordered structure [12]. Raman spectra provide 
two specific bands for secondary structure of the 
polypeptide backbone, known as amide bands and 
are related with a peptide linkage between amino 
acids in the proteins. Amide I band is referred to 
different stretching vibration of C=O bond. 
 
 
Figure 3. 
Raman spectra of Trastuzumab 1 mg/mL; p-SCN-
Bn-DTPA-Trastuzumab (1:10); p-SCN-Bn-DTPA-
Trastuzumab (1:50); p-SCN-Bn-1B4M-DTPA-
Trastuzumab (1:10); p-SCN-Bn-1B4M-DTPA-
Trastuzumab (1:50) 
 
If the polypeptide backbone is predominantly α 
helix the Amide I band would appear at ~ 1655 cm-1. 
Monoclonal antibodies and the other molecules that 
contain primarily β-sheet have shown characteristic 
Amide I band at ~ 1670 cm-1 [15, 31]. In the spectra 
of pure trastuzumab (1676 cm-1) and the other four 
immunoconjugates: (1:10) p-SCN-Bn-DTPA- (1674 
cm-1), (1:50) p-SCN-Bn-DTPA- (1676 cm-1), (1:10) 
p-SCN-Bn-1B4M-DTPA- (1676 cm-1), (1:50) p-SCN-
Bn-1B4M-DTPA- (1678 cm-1), the characteristic 
Amide I band were detected, which has shown the 
retention of α-helix in all samples. Amide III band, 
associated with coupled C-N stretching and N-H 
bending vibrations of the peptide group, is also 
important for determination of protein secondary 
structure (β-sheet structure) and was registered 
between 1230 cm-1 and 1300 cm-1. In α-helix arranged 
proteins this band occurs at interval between 1300 
cm-1 and 1340 cm-1. Monoclonal antibodies primarily 
contain β-barrel structure and provide Amide III 
band at ~ 1245 cm-1 [1, 20, 24, 32]. The presence of 
Amide III band in the collected spectra of trastuzumab-
immunoconjugates in comparison with Raman spectra 
of pure trastuzumab (1245 cm-1), (1:10) p-SCN-Bn-
DTPA- (1255 cm-1), (1:50) p-SCN-Bn-DTPA- (1227 
cm-1), (1:10) p-SCN-Bn-1B4M-DTPA- (1226 cm-1), 
(1:50) p-SCN-Bn-1B4M-DTPA- (1235 cm-1), has 
shown no modification of the antibody secondary 
structure and the retention of β-sheet structure. Raman 
bands of aromatic amino acids in proteins are clearly 
visible in Raman spectra, but can be covered with 
amide bands of other side chain groups. The presence 
of well-defined tryptophan (trp), phenylalanine (phe) 
and tyrosine (tyr)  bands (400-4000 cm-1) are in 
accordance with the previously published data [5, 6, 
9, 16, 23, 26, 31] (pure trastuzumab (trp-765 cm-1, 
865 cm-1, 1332 cm-1, phe-1010 cm-1, tyr-650 cm-1), 
(1:10) p-SCN-Bn-DTPA- (trp-764 cm-1, 878 cm-1, 
1328 cm-1, phe-1056 cm-1, tyr-647 cm-1), (1:50) p-
SCN-Bn-DTPA- (trp-762 cm-1, 886 cm-1, 1328 cm-1, 
phe-1022 cm-1, tyr-648 cm-1), (1:10) p-SCN-Bn-
1B4M-DTPA- (trp-762 cm-1, 879 cm-1, 1328 cm-1, 
phe-1022 cm-1, tyr-645 cm-1), (1:50) p-SCN-Bn-
1B4M-DTPA- (trp-757 cm-1, 878 cm-1, 1328 cm-1, 
phe-1040 cm-1, tyr-648 cm-1)). The majority of the 
proteins have shown Raman bands of free 
sulfhydryl and disulphide bonds. According to 
already published results [9, 31] in our samples, 
pure trastuzumab (471cm-1, 510 cm-1), (1:10) p-
SCN-Bn-DTPA- (479 cm-1, 528 cm-1), (1:50) p-
SCN-Bn-DTPA- (425 cm-1, 489 cm-1, 519 cm-1), 
(1:10) p-SCN-Bn-1B4M-DTPA- (479 cm-1, 488 
cm-1, 527 cm-1), (1:50) p-SCN-Bn-1B4M-DTPA- 
(479 cm-1, 496 cm-1, 521 cm-1) were detected 
disulphide bands in region between 540 and 400 
cm-1. No significant variations in Raman spectra of 
immunoconjgates supported by positive SDS-
PAGE results have shown unchanged protein 
structure, without any aggregation after process of 
conjugation and lyophilisation. 
 
Conclusions 
The obtained results have undoubtedly confirmed no 
integrity change and no physicochemical and structural 
modifications of trastuzumab after p-SCN-Bn-DTPA- 
and p-SCN-Bn-1B4M-DTPA- conjugation in the 
process of freeze drying. The lyophilized kit 
formulations, due to increased stability allow prolonged 
storage and extension of the shelf life of the anti-
body. An appearance of two bands of fragments (25 
kDa for light chain and 50 kDa for heavy chain) on 
electrophoretic gels revealed that no degradation of 
the antibody took place. The obtained results from 
the collected Raman spectra (especially the presence 
of Amide I and III bands) also demonstrate retained 
secondary β-sheet structure. Therefore, this work 
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supports the opportunity for further determination of 
the number of the chelators attached to the antibody 
with Matrix Assisted Laser Desorption Ionization 
Time of Flight Mass Spectrometer (MALDI-TOF-MS) 
and development of radiopharmaceuticals for imaging 
and treatment of HER2 positive breast tumours. 
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